Dummy tablets

DRUG2 trials

Sponsors

Spero Therapeutics

Conditions

Acute PyelonephritisComplicated Urinary Tract InfectionUrinary Tract Infection

Phase 3

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

CompletedNCT03788967

Spero TherapeuticsAcute Pyelonephritis, Complicated Urinary Tract Infection

Start: 2019-06-03End: 2020-05-27Updated: 2022-07-25

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

CompletedNCT06059846

Spero TherapeuticsAcute Pyelonephritis, Urinary Tract Infection

Start: 2023-12-21End: 2025-02-06Updated: 2026-03-10

Related Papers

173. Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study

Open Forum Infectious Diseases2026-01-01

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection

New England Journal of Medicine2022-04-0670 citations